VanEck Pharmaceutical ETF
PPH

$96.26

0.95%

Market Cap: $726M

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

41% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 32

2% more funds holding

Funds holding: 132 [Q1] → 134 (+2) [Q2]

8% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 24

4% more capital invested

Capital invested by funds: $416M [Q1] → $432M (+$16.3M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

4.94% less ownership

Funds ownership: 77.21% [Q1] → 72.27% (-4.94%) [Q2]

76% less call options, than puts

Call options by funds: $977K | Put options by funds: $4.03M

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for PPH.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Looking for broad exposure to the Healthcare - Pharma segment of the equity market? You should consider the VanEck Pharmaceutical ETF (PPH), a passively managed exchange traded fund launched on 12/20/2011.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

This Pharma ETF Could Be Ideal Healthcare Pick

Broadly speaking, the healthcare sector remains a laggard relative to the broader market. As of Aug. 28, the S&P Select Sector Health Care Index was trailing the S&P 500 by 310 basis points on a year-to-date basis.

This Pharma ETF Could Be Ideal Healthcare Pick

Zacks Investment Research

Pharma ETFs in Focus Post Solid Q2 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

Pharma ETFs in Focus Post Solid Q2 Earnings

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

PPH: A Strong Fund To Play Big Pharma

The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat recession-proof, but high costs and regulatory risks are potential drawbacks.

PPH: A Strong Fund To Play Big Pharma

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Launched on 12/20/2011, the VanEck Pharmaceutical ETF (PPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Zacks Investment Research

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

The VanEck Pharmaceutical ETF (PPH) was launched on 12/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Pharma segment of the equity market.

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

Thematic ETF Winners of the Q1 2024 Earnings Season

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Thematic ETF Winners of the Q1 2024 Earnings Season

Zacks Investment Research

A Look at Pharma ETFs Post Q1 Earnings

Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.

A Look at Pharma ETFs Post Q1 Earnings

Zacks Investment Research

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.

ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook

See News Rankings